The Definitive Guide to Setting Up Life Sciences Global Capability Centres (GCCs) in Hyderabad, India in 2026-2027

Jai Shri Krishna. Hyderabad is the undisputed Life Sciences Global Capability Centre (GCC) capital of India and one of the three most important Life Sciences clusters in the world outside Boston-Cambridge and Basel-Zurich. Genome Valley, India's first organised cluster for Life Sciences research, biotechnology and vaccines, is anchored in Hyderabad. In Financial Year (FY) 2025 and the first half of FY 2026, Hyderabad captured the largest share of net new Life Sciences Global Capability Centre (GCC) announcements globally. This pillar guide is the single most comprehensive public document on building a Life Sciences Global Capability Centre (GCC) in Hyderabad, covering clinical development, biometrics, regulatory affairs, medical affairs, pharmacovigilance, real world evidence, biologics, cell and gene therapy, vaccines, diagnostics and medical devices.

1. Executive Summary

• Hyderabad produces approximately 12,000 Master of Science (MSc) and Doctor of Philosophy (PhD) graduates per year in Biotechnology, Biochemistry, Microbiology, Pharmacology, Pharmaceutics, Bioinformatics, Biostatistics and Clinical Research streams, the largest such pool in India.
• The Genome Valley cluster hosts more than 200 Life Sciences organisations including Bharat Biotech, Biological E, Indian Immunologicals, Shantha Biotechnics (Sanofi), Dr. Reddy's Laboratories, Aurobindo Pharma, Divi's Laboratories, Laurus Labs, Hetero, MSN Laboratories, Granules India, Lupin, Suven, Syngene, Novartis Biome, Pfizer, GlaxoSmithKline (GSK), AstraZeneca, Sanofi, Bayer, Merck, Johnson and Johnson, Bristol Myers Squibb (BMS), Eli Lilly, Boehringer Ingelheim, Novo Nordisk and Takeda.
• Fully loaded cost per Full-Time Equivalent (FTE) for a mid-level Biostatistician or Clinical Data Manager (CDM) in Hyderabad is 12 per cent to 18 per cent lower than Bangalore and 8 per cent to 14 per cent lower than Pune. The cost arbitrage versus a comparable Life Sciences professional in Boston, New Jersey, Basel, London or Singapore is 68 per cent to 78 per cent.
• Voluntary attrition in Hyderabad Life Sciences Global Capability Centres (GCCs) ran at 11 per cent to 15 per cent through FY 2026, materially below the Bangalore range of 18 per cent to 24 per cent for technology talent.
• Genome Valley, HITEC City, Financial District, Gachibowli, Kondapur, Madhapur, Nanakramguda, Pocharam and the Adibatla industrial corridor collectively offer 95 million plus square feet of Grade A office stock. Office rent in prime Hyderabad micro-markets is INR 60 to INR 95 per square foot per month versus INR 95 to INR 160 in Outer Ring Road (ORR) Bangalore.
• A 300 Full-Time Equivalent (FTE) Life Sciences Global Capability Centre (GCC) in Hyderabad can be productive within 9 to 12 months of board approval if structured as a private limited company under the Companies Act 2013 and operated under the Central Board of Direct Taxes (CBDT) safe harbour at 17 per cent to 18 per cent cost plus.
• Generative Artificial Intelligence (AI) has compressed the productivity curve of every Life Sciences role from medical writing to clinical study report generation to literature review to safety signal detection. A 200 Full-Time Equivalent (FTE) Life Sciences Global Capability Centre (GCC) in 2026 produces the throughput of a 320 Full-Time Equivalent (FTE) Life Sciences Global Capability Centre (GCC) of 2022.
• Build-Operate-Transfer (BOT) with an Integrated Partner like ChirayuGCC, transferring at month 24 or month 30, is the lowest risk path to a captive Life Sciences Global Capability Centre (GCC) in Hyderabad for parents below USD 5 billion in revenue.

2. Why Hyderabad, Specifically for Life Sciences

2.1 The Genome Valley advantage

Genome Valley, launched in 1999 by the Government of Andhra Pradesh and later inherited by the Government of Telangana, is India's first organised Life Sciences cluster and remains the deepest in the country. It spans Shamirpet, Turkapally and Karkapatla covering over 600 acres of dedicated Life Sciences research, manufacturing and Global Capability Centre (GCC) infrastructure with Biosafety Level 3 (BSL 3) capable wet lab space, vivariums, pilot manufacturing facilities and the Centre for DNA Fingerprinting and Diagnostics (CDFD), the Centre for Cellular and Molecular Biology (CCMB), the National Institute of Animal Biotechnology (NIAB), the Indian Institute of Chemical Technology (IICT) and the National Institute of Nutrition (NIN) all in adjacent campuses.

2.2 The Pharma City and Bulk Drug Park

The upcoming Hyderabad Pharma City at Mucherla, spread over 19,000 acres, is the world's largest integrated pharmaceutical and Life Sciences cluster under development. The Bulk Drug Park designation under the Ministry of Chemicals and Fertilizers Production Linked Incentive (PLI) scheme adds a further USD 3 billion of incentive capacity for Active Pharmaceutical Ingredient (API) and Key Starting Material (KSM) manufacturing through 2030.

2.3 The talent thesis

Hyderabad is home to the University of Hyderabad, Osmania University, Jawaharlal Nehru Technological University (JNTU) Hyderabad, the National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad, the Indian Institute of Technology (IIT) Hyderabad, the International Institute of Information Technology (IIIT) Hyderabad, Birla Institute of Technology and Science (BITS) Hyderabad and dedicated Life Sciences institutes at Indian School of Business (ISB) and the Indian Institute of Chemical Technology (IICT). The supplementary corridor of Warangal, Vijayawada, Visakhapatnam and Tirupati feeds another 8,000 to 10,000 Life Sciences postgraduates a year into Hyderabad.

2.4 The clinical research depth

Hyderabad hosts approximately 35 per cent of all phase 1, phase 2 and phase 3 clinical trials run in India in FY 2025. The depth of Contract Research Organisations (CROs), Clinical Research Associates (CRAs), Clinical Data Managers (CDMs), Biostatisticians, Programmers and Medical Writers in Hyderabad is the deepest in India.

2.5 The biologics, vaccines, cell and gene therapy edge

Hyderabad is home to Bharat Biotech (Covaxin), Biological E (Corbevax), Indian Immunologicals, Shantha Biotechnics, Bharat Serums and the upcoming cell and gene therapy facilities of Dr. Reddy's, Aurobindo and Laurus. The biologics, vaccines and advanced therapies depth is structurally different from Pune, Bangalore or Ahmedabad.

3. The Hyderabad Micro-Market Map

• Genome Valley (Shamirpet, Turkapally, Karkapatla), 600 plus acres of dedicated Life Sciences infrastructure with wet lab, vivarium and pilot manufacturing. Best for biologics, vaccines, biosimilars, cell and gene therapy and wet lab anchored Global Capability Centres (GCCs).
• HITEC City, Madhapur, Kondapur and Gachibowli, 45 million plus square feet of Grade A stock. Anchor tenants include Microsoft, Google, Amazon, Meta, Apple, Salesforce, Oracle, ServiceNow, Uber, Goldman Sachs, Wells Fargo, JP Morgan, State Street and the Indian Global Capability Centres (GCCs) of Pfizer, Sanofi, Bayer, Eli Lilly, Novartis and Bristol Myers Squibb (BMS). Rent INR 65 to INR 90 per square foot per month. Best for clinical, biometrics, regulatory and medical Global Capability Centres (GCCs).
• Financial District and Nanakramguda, 18 million plus square feet of Grade A stock. Best for premium positioning, senior leadership comfort and the Life Sciences technology overlay.
• Raidurg and Knowledge City, 12 million plus square feet of integrated campus stock. Best for large single tenant Life Sciences Global Capability Centres (GCCs) of 1,500 plus Full-Time Equivalents (FTEs).
• Pocharam, Adibatla and Mucherla, emerging corridors with 8 million plus square feet at INR 45 to INR 65 per square foot per month. Best for cost optimised volume operations co-located with manufacturing and Pharma City.

4. The Life Sciences Global Capability Centre (GCC) Charter

4.1 Clinical Development Operations

• Clinical Trial Management System (CTMS) administration on Veeva Vault CTMS, Medidata Rave CTMS and Oracle Argus
• Clinical Trial Application (CTA), Investigational New Drug (IND), New Drug Application (NDA), Biologics License Application (BLA) and Marketing Authorisation Application (MAA) operations support
• Clinical Study Report (CSR) writing under International Council for Harmonisation (ICH) E3 guidelines
• Site management, site activation, monitoring oversight and risk based monitoring (RBM)
• Investigator Brochure (IB), Informed Consent Form (ICF) and Protocol authoring
• Trial Master File (TMF) management on Veeva Vault eTMF and Oracle eClinical
• Decentralised Clinical Trials (DCT), virtual trials and hybrid trial operations

4.2 Biometrics, Statistics and Programming

• Biostatistics, study design, Statistical Analysis Plan (SAP) authoring, sample size calculation, adaptive design and Bayesian methods
• Statistical Analysis System (SAS) programming, R programming and Python programming for clinical analytics
• Clinical Data Management (CDM) on Medidata Rave, Veeva Vault Electronic Data Capture (EDC), Oracle Clinical and Inform
• Clinical Data Interchange Standards Consortium (CDISC), Study Data Tabulation Model (SDTM) and Analysis Data Model (ADaM) conversion
• Define-XML, Reviewer's Guide and electronic submission preparation
• Statistical reporting, Tables Listings and Figures (TLF) generation, in-text tables and patient profiles
• Real World Evidence (RWE) analytics, claims data analysis, electronic health record (EHR) studies

4.3 Regulatory Affairs

• Regulatory strategy for the United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA) of Japan, National Medical Products Administration (NMPA) of China, Central Drugs Standard Control Organisation (CDSCO) of India and Therapeutic Goods Administration (TGA) of Australia
• electronic Common Technical Document (eCTD) publishing on Lorenz docuBridge and Extedo eCTDmanager
• Module 1, 2, 3, 4 and 5 authoring and quality control
• Health Authority query response, label negotiation and lifecycle management
• Chemistry Manufacturing and Controls (CMC) regulatory writing
• Pharmacovigilance regulatory submissions, Periodic Safety Update Reports (PSURs) and Development Safety Update Reports (DSURs)
• Medical Device regulatory submissions, 510(k), Premarket Approval (PMA), CE marking and Medical Device Regulation (MDR) compliance

4.4 Pharmacovigilance and Drug Safety

• Individual Case Safety Report (ICSR) processing, MedDRA coding and case quality review
• Signal detection, signal evaluation and risk management plans
• Periodic Safety Update Reports (PSURs), Periodic Benefit Risk Evaluation Reports (PBRERs) and Risk Management Plans (RMPs)
• Literature surveillance on Embase, PubMed, Scopus and proprietary databases
• Aggregate safety reporting and post marketing surveillance
• Pharmacovigilance database administration on Oracle Argus, ArisGlobal LifeSphere and Veeva Vault Safety

4.5 Medical Affairs and Medical Writing

• Medical writing, manuscripts, congress abstracts, posters and slide decks
• Medical Information (MI) call centre support and standard response document maintenance
• Medical Science Liaison (MSL) support, scientific exchange materials and key opinion leader (KOL) mapping
• Health Economics and Outcomes Research (HEOR), Real World Evidence (RWE) and value dossier development
• Publication planning, GPP3 compliance and authorship management

4.6 Quality, Compliance and Good Practice (GxP)

• Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Good Manufacturing Practice (GMP) and Good Pharmacovigilance Practice (GVP) compliance
• Computer System Validation (CSV) and Good Automated Manufacturing Practice (GAMP 5)
• 21 Code of Federal Regulations (CFR) Part 11 and EU Annex 11 compliance
• Quality Management System (QMS) administration
• Internal audit, vendor audit and Health Authority inspection readiness

4.7 Wet Lab and Translational Capability (Genome Valley anchored)

• Discovery biology, target validation, assay development and high throughput screening (HTS)
• Medicinal chemistry, computational chemistry and structure based drug design
• Pre-clinical pharmacology, toxicology and Drug Metabolism and Pharmacokinetics (DMPK)
• Biologics discovery, antibody engineering, cell line development and process development
• Cell and gene therapy, viral vector production and analytical method development
• Bioanalytical, bioassay and chemistry analytical method development

5. The Compensation Bands, Hyderabad Life Sciences Global Capability Centre (GCC), 2026-2027

All numbers are total cash (Total Fixed Compensation plus Annual Variable) for the 50th percentile in Indian Rupees (INR) lakh per annum. Add 15 per cent to 20 per cent for fully loaded cost.

• Clinical Research Associate (CRA), 2 to 5 years: INR 11 to INR 18 lakh per annum
• Senior Clinical Research Associate (Senior CRA), 5 to 8 years: INR 18 to INR 30 lakh per annum
• Clinical Project Manager (CPM): INR 28 to INR 48 lakh per annum
• Clinical Data Manager (CDM), 3 to 6 years: INR 14 to INR 24 lakh per annum
• Senior Clinical Data Manager (Senior CDM), 6 to 10 years: INR 24 to INR 42 lakh per annum
• Biostatistician, 2 to 5 years: INR 16 to INR 28 lakh per annum
• Senior Biostatistician, 5 to 9 years: INR 28 to INR 50 lakh per annum
• Principal Biostatistician: INR 50 to INR 90 lakh per annum
• Statistical Analysis System (SAS) Programmer 2: INR 14 to INR 24 lakh per annum
• Senior Statistical Analysis System (SAS) Programmer: INR 24 to INR 42 lakh per annum
• Regulatory Affairs Associate: INR 12 to INR 20 lakh per annum
• Regulatory Affairs Manager: INR 28 to INR 48 lakh per annum
• Regulatory Affairs Director: INR 60 lakh to INR 1.2 crore per annum
• Pharmacovigilance Associate: INR 8 to INR 14 lakh per annum
• Pharmacovigilance Manager: INR 22 to INR 38 lakh per annum
• Pharmacovigilance Director: INR 55 lakh to INR 1.0 crore per annum
• Medical Writer: INR 16 to INR 28 lakh per annum
• Senior Medical Writer: INR 28 to INR 48 lakh per annum
• Medical Director: INR 80 lakh to INR 1.8 crore per annum
• Discovery Scientist (PhD), Wet Lab: INR 22 to INR 40 lakh per annum
• Principal Scientist (PhD): INR 50 lakh to INR 1.1 crore per annum
• Head of Clinical Operations: INR 1.5 to INR 3.0 crore per annum
• Head of Biometrics: INR 1.5 to INR 3.0 crore per annum
• Country Head: INR 3.5 to INR 7.5 crore per annum

6. The Architecture of the Hyderabad Life Sciences Global Capability Centre (GCC), Four Towers

We recommend the Four Tower architecture for a Hyderabad Life Sciences Global Capability Centre (GCC) sized 200 to 1,200 Full-Time Equivalents (FTEs). Tower 1 is Clinical Operations. Tower 2 is Biometrics and Data. Tower 3 is Regulatory, Safety and Medical. Tower 4 is Wet Lab and Translational (only for biologics, vaccines, cell and gene therapy parents).

7. Talent Strategy, How to Win the Top Quartile in Hyderabad

• Establish the Genome Valley brand within 90 days through public scientific talks at the Centre for Cellular and Molecular Biology (CCMB), the Indian Institute of Chemical Technology (IICT) and the National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad
• Hire the first 5 Principal Scientists, Principal Biostatisticians and Director Regulatory Affairs personally through founder or Chief Scientific Officer (CSO) level conversations
• Partner with 4 to 6 specialist Life Sciences recruitment boutiques in Hyderabad
• Run a structured Returning Mothers Program for senior women scientists and biometricians
• Run a structured PhD residency program with the University of Hyderabad, NIPER and IIT Hyderabad
• Run a dedicated generative Artificial Intelligence (AI) for Life Sciences apprenticeship for every joiner
• Set Hyderabad attrition target at 11 to 15 per cent

8. Real Estate, Phased Build Out

• Phase 0, months 1 to 6, 30 to 80 FTEs, 6,000 to 15,000 sq ft of managed office in HITEC City or Gachibowli, CAPEX under USD 200,000
• Phase 1, months 7 to 18, 80 to 250 FTEs, 25,000 to 45,000 sq ft of fitted out office in Madhapur, Kondapur or Nanakramguda, CAPEX USD 1.0 million to USD 2.2 million
• Phase 2, months 19 to 36, 250 to 500 FTEs, 55,000 to 90,000 sq ft in Financial District or Knowledge City, CAPEX USD 2.5 million to USD 4.5 million
• Phase 3, months 37 to 60, 500 to 1,000 FTEs, 100,000 to 200,000 sq ft single tenant block in Raidurg or Knowledge City, CAPEX USD 5.0 million to USD 11.0 million
• Wet lab overlay at Genome Valley: 15,000 to 60,000 sq ft of BSL 2 and BSL 3 lab fit out, additional CAPEX USD 6 million to USD 22 million

9. Regulatory, Tax and Compliance Posture

• Companies Act 2013 private limited company structure with RBI compliant FDI inflows on automatic route
• Income Tax: 17 per cent to 18 per cent cost plus under Central Board of Direct Taxes (CBDT) safe harbour for Knowledge Process Outsourcing (KPO) services, or full Transfer Pricing study
• Goods and Services Tax (GST): 18 per cent on inter-company recharge, refundable on export under Letter of Undertaking (LUT)
• Digital Personal Data Protection (DPDP) Act 2023 compliance with explicit consent workflows for clinical and patient data
• Indian Council of Medical Research (ICMR) ethical guidelines and Central Drugs Standard Control Organisation (CDSCO) New Drugs and Clinical Trials Rules 2019
• Drugs and Cosmetics Act 1940 and Rules 1945
• 21 CFR Part 11, EU Annex 11, ICH E6 (R3) Good Clinical Practice (GCP) and ICH E9 (R1) statistical principles
• Biosafety guidelines under the Department of Biotechnology (DBT) and Review Committee on Genetic Manipulation (RCGM)

10. The 30 60 90 Day Launch Plan

10.1 Days 1 to 30

• Incorporate the private limited company through MCA SPICe Plus
• Open RBI compliant bank account and file FDI reporting through FIRMS
• Sign managed office lease in HITEC City or Gachibowli
• Hire Country Head, Head of Clinical Operations, Head of Biometrics, Head of Regulatory and Head of People
• Stand up entity IT, identity, SSO, MFA, endpoint, MDM and 21 CFR Part 11 compliant validated environment

10.2 Days 31 to 60

• Hire first 20 to 40 Clinical Research Associates (CRAs), Clinical Data Managers (CDMs), Biostatisticians, SAS Programmers and Regulatory Associates
• Stand up Veeva Vault CTMS, Veeva Vault eTMF, Medidata Rave EDC, SAS, R, Argus and eCTD publishing tools
• Run first 2 week Onsite Immersion at the parent for first cohort
• Define SOPs, work instructions and Quality Management System (QMS) for the first 5 Standard Operating Procedures
• Sign Phase 1 fitted out lease

10.3 Days 61 to 90

• Take ownership of first independent deliverables: first independently managed clinical study, first SDTM dataset, first eCTD module
• Stand up the Quality dashboard and Computer System Validation (CSV) framework
• Run first Quarterly Business Review (QBR) with parent Chief Scientific Officer (CSO)
• Hire next 40 to 80 FTEs and close offers for next 60 to 100

11. The Economic Case, 300 FTE Hyderabad Life Sciences GCC at Steady State

A 300 Full-Time Equivalent (FTE) Hyderabad Life Sciences Global Capability Centre (GCC) at steady state runs at USD 18 million to USD 26 million per year all-in. The equivalent bench at the parent in Boston, New Jersey, Basel, London, Tokyo or Singapore would cost USD 80 million to USD 130 million. The annual cost arbitrage is USD 60 million to USD 105 million.

• Year 1: 0 to 100 FTEs, OPEX USD 5 million to USD 8 million
• Year 2: 100 to 220 FTEs, OPEX USD 12 million to USD 18 million
• Year 3: 220 to 300 FTEs, OPEX USD 18 million to USD 26 million
• Generative Artificial Intelligence (AI) productivity uplift: USD 6 million to USD 14 million of equivalent throughput per year
• Net Present Value (NPV) over 7 years at 12 per cent discount rate: USD 260 million to USD 440 million

12. Hyderabad Versus Pune Versus Bangalore for Life Sciences

• Hyderabad: deepest Life Sciences talent pool, deepest clinical research and biometrics depth, best for biologics, vaccines, cell and gene therapy and the largest single city Life Sciences cluster
• Pune: strong for Pharmacovigilance, Medical Writing, Regulatory and Clinical Data Management, lower attrition than Hyderabad for those specific functions, best as a complementary second city
• Bangalore: best for Life Sciences technology overlay, Real World Evidence (RWE) analytics, AI for Drug Discovery and platform engineering for Life Sciences products, not for clinical operations or regulatory depth

13. BOT, Managed GCC and Direct Setup

Most mid-market Life Sciences parents benefit from a 24 to 36 month Build-Operate-Transfer (BOT) or Managed Global Capability Centre (GCC) construct with an Integrated Partner, transferring to captive at maturity.

14. The ChirayuGCC Approach

ChirayuGCC has been involved in the setup, scale up and operating model design of multiple Hyderabad Life Sciences, Pharma and Biotech Global Capability Centres (GCCs). Our approach is rooted in deep clinical, regulatory and Life Sciences operating experience.

15. Frequently Asked Questions

• Hyderabad or Bangalore for a first Life Sciences Global Capability Centre (GCC)? Hyderabad for clinical, biometrics, regulatory, safety and wet lab; Bangalore only for Life Sciences technology overlay
• Can the Hyderabad Global Capability Centre (GCC) own end to end Clinical Study Reports (CSRs)? Yes
• Realistic fully loaded cost arbitrage versus Boston, Basel, London, Tokyo or Singapore? 68 per cent to 78 per cent
• How does generative Artificial Intelligence (AI) change the headcount plan? Plan 30 to 40 per cent lower than 2022 baselines

16. References and Further Reading

• Central Drugs Standard Control Organisation (CDSCO), New Drugs and Clinical Trials Rules 2019: cdsco.gov.in
• Indian Council of Medical Research (ICMR), National Ethical Guidelines for Biomedical and Health Research: www.icmr.gov.in
• Department of Biotechnology (DBT), Government of India: dbtindia.gov.in
• Telangana Life Sciences and Pharma Policy 2025: www.telangana.gov.in
• Genome Valley Telangana: www.tslifesciences.com
• International Council for Harmonisation (ICH), E6 (R3) Good Clinical Practice (GCP): www.ich.org
• United States Food and Drug Administration (US FDA), Center for Drug Evaluation and Research (CDER): www.fda.gov
• European Medicines Agency (EMA): www.ema.europa.eu
• Pharmaceuticals and Medical Devices Agency (PMDA) of Japan: www.pmda.go.jp
• Reserve Bank of India (RBI), Foreign Exchange Management Regulations: www.rbi.org.in
• Central Board of Direct Taxes (CBDT), Safe Harbour Rules: incometaxindia.gov.in
• India Brand Equity Foundation (IBEF), Pharmaceuticals and Biotech sector reports: www.ibef.org

Closing read

Hyderabad is the only city in the world where Genome Valley wet lab depth, clinical research density, biometrics scale and biologics manufacturing converge in a single 30 kilometre radius. The operating model that compounds is a Four Tower architecture in HITEC City or Knowledge City with a wet lab overlay at Genome Valley, an 11 to 15 per cent attrition target, generative Artificial Intelligence (AI) readiness from Day 1 and a BOT or Managed GCC construct that transfers at month 24 or 30. ChirayuGCC is the Integrated Partner. Jai Shri Krishna.